ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL INDUSTRY THE FUTURE

[1] Mohamed Ajmal A S, [2] Satish Birhare*
[1] *PG Student, Department of Pharmacy, Annamalai University, Annamalai Nagar.*
[2] *Manager, Accent Pharma, Puducherry.*
(E-mail: satish_c_b@yahoo.co.in)

Abstract— The shift to Industry 4.0 within pharmaceutical manufacturing sector, known as Pharma 4.0, signifies a notable advancement driven by digitalization and automation. This transition integrates state-of-the-art technologies such as the Artificial Intelligence (AI), Internet of Things (IoT), big data analytics, and robotics to transform manufacturing processes significantly. Pharma 4.0 offers numerous benefits, including enhanced efficiency, improved quality control, better regulatory compliance, and quicker introduction of new drugs to market. However, implementing it presents several challenges, including the need for substantial investment, adherence to regulations, concerns about data privacy and security, integration of existing systems, recruitment and retention of skilled personnel, cost considerations, and protection of intellectual property. Despite these challenges, the potential long-term advantages of Industry 4.0 adoption make it a strategic move for pharmaceutical companies seeking to drive innovation and maintain competitiveness in the rapidly changing healthcare landscape.

Keywords— *Industry 4.0, Pharma 4.0, Pharmaceutical manufacturing, Artificial Intelligence (AI), Digitalization, Automation, Internet of Things (IoT), Quality Management System (QMS), Quality by Design (QbD), Efficiency, Challenges.*

I. INTRODUCTION

The term Industry 4.0 signifies the fourth industrial revolution, marking the convergence of rapidly advancing technologies, which are reshaping the manufacturing landscape. Industry 4.0 is characterized by the development of autonomous, integrated, and self-organizing production systems. In the realm of human resource management, numerous challenges arise in managing time, spanning from pre-formulation studies to product marketing. Therefore, artificial intelligence (AI) can play a vital role in aiding them to handle these tasks with intelligence and efficiency. Artificial Intelligence is the ability of digital computers to perform tasks that are normally performed by intelligent individuals. Presently, artificial intelligence (AI) and machine learning (ML) involve replicating human intelligence patterns and processes through small robotic systems and computer system. [1-5]

II. HISTORY

The second Industrial Revolution 2.0, which was mostly driven by the widespread use of electricity, began a dramatic transition from individual or small-scale manufacturing to large-volume mass production at the beginning of the 20th century. In the 21st century, Industry 4.0 marks the fourth Industrial Revolution, aiming to seamlessly integrate cyber-physical systems with information, processes, equipment, and operational technologies. This integration is facilitated by the widespread utilization of the IoT and associated services, in conjunction with advanced techniques such as big data analytics and artificial intelligence. [6-8]

These advancements necessitate the application of artificial intelligence approaches across various domains, ranging from identifying popular television shows to discovering lead molecules and developing therapeutic compounds, including clinical trials. Therefore, fostering innovation within the pharmaceutical industry becomes crucial to enhance the precision and speed of medicine production. [9].

III. STAGES OF INDUSTRIAL REVOLUTION

A. Industry 1.0:

During the first phase of industrial development, there was a shift from manual handling of animal sourced material, botanical, and mineral to the utilization of large-scale machinery capable of processing greater quantities of medicines through crushing, milling, blending, and pressing.

B. Industry 2.0:

Electricity and the first electronic gadgets, as well as assembly lines with basic automation and process controls, all contributed to the second industrial revolution. These developments gave manufacturers the authority to set basic process parameters.

C. Industry 3.0:

With the development and widespread availability of computer technology and communication platforms including networked computing, the internet, and wireless communication, the third industrial revolution was born. These developments made it easier to automate machinery and processes more.

D. Industry 4.0:

Modern manufacturing technologies are combined in the fourth industrial revolution to form integrated, self-sufficient, and self-regulating production systems that can operate without the need for human intervention. Manufacturing processes are revolutionised during this period, which the pharmaceutical industry refers to as Pharma 4.0. [10-13] Detailed Stages of Revolution shown in Fig. 1.



"Fig. 1. Stages of Industrial Evolutions"

IV. BENEFITS OF "INDUSTRY 4.0" TO THE PHARMACEUTICAL MANUFACTURING UNITS

The evolution of manufacturing through four transformative stages has culminated in Pharma 4.0, marking the advancement of the pharma industry through the integration of cutting-edge technologies and digital strategies. Incorporating concepts from Industry 4.0 into pharmaceutical practices holds promise for overcoming the challenges encountered within the sector. Industry 4.0's role in pharmaceuticals is to facilitate the design and production of innovative, personalized products tailored to varying customer preferences and demands quickly, economically, and efficiently. Simple Ideology of Pharma 4.0 shown in Fig. 2.

Illustrating the automation and digitalization within the pharmaceutical sector through case-based adaptation and demonstration highlights the potential benefits. However, numerous challenges arise due to regulatory compliance requirements specific to the pharma industry. Embracing "Industry 4.0" within pharmaceuticals will propel the sector towards Pharma 4.0, enhancing transparency and accelerating processes within manufacturing plants.

"Fig. 2. Ideology of Pharma 4.0"

This transition promises quicker decision-making processes and improved overall control and security. Successful implementation hinges on aligning expectations, interpretations, and definitions with pharmaceutical regulations. [17-19]

A. Enhanced Quality through Comprehensive Production Oversight:

Pharma 4.0 presents a range of digital capabilities, including remote monitoring of manufacturing equipment and predictive maintenance. By identifying manufacturing inefficiencies, it helps prevent batch failures, adhering to a comprehensive approach that spans from optimizing raw material selection to minimizing process variations.

B. Cost Reductions

Utilizing Pharma 4.0 enables companies to automate manual tasks, minimize downtime, and decrease waste, thereby reducing costs. Simultaneously, the heightened quality standards associated with Pharma 4.0 can help mitigate expenses related to recalls and other quality-related issues.

C. Enhanced Compliance:

With its enhanced visibility into pharmaceutical manufacturing processes, Pharma 4.0 assists companies in maintaining compliance with regulations. Automated data collection and analysis further aid in swiftly identifying and rectifying deviations from standard operating procedures.

D. Increased Flexibility:

Pharma 4.0 empowers companies to enhance flexibility by allowing for the reconfiguration of manufacturing processes. This adaptability can accommodate fluctuations in product demand or facilitate the rapid introduction of new products to the market.

E. Improved Safety and Enhanced Outcomes:

The capability to track products throughout the supply chain enhances product quality and safety. Additionally, automating pharmaceutical manufacturing processes reduces workers' exposure to hazardous materials, improving overall safety. Impact and Benefits of Health 4.0 Shown in Fig. 3



"Fig. 3. Impact of Health 4.0"

F. Real-time Monitoring:

Shifting away from paper-based processes, real-time monitoring fosters greater connectivity across departments and boosts productivity.

G. Integration of People, Processes, and Technology:

Leveraging the Industrial Internet of Things and Cyber-Physical Systems (CPS), Pharma 4.0 enhances connectivity and productivity by seamlessly integrating human operators with pharmaceutical technology. [14-17].

V. TRANSITIONING FROM INDUSTRY 4.0 TO THE PHARMA 4.0 OPERATING MODEL:

The fusion of the International Council of Harmonisation (ICH) principles with Industry 4.0 concepts gives rise to the Pharma 4.0 operating model. The International Society for Pharmaceutical Engineering, along with its members, has crafted the Pharma 4.0 Operating Model.

A. Comprehensive Digital Empowerment:

Ways for providing all-inclusive digital solutions that guarantee a consistent, dependable, and advanced Pharma 4.0 implementation.

B. Mapping Processes and Critical Analysis:

Techniques for developing process and data mapping leading to virtual modeling.

C. Plug and Play Integration:

Facilitating the shift from centralized systems to modular, distributed, and autonomous manufacturing services.

D. Validation 4.0:

Introducing a less complex validation model as a new paradigm.

E. Management Communication Strategy:

Creating an elevator pitch for Pharma 4.0 that is understood by management.

F. Continuous Process Verification and Automation:

Implementing methods for parametric release, emphasizing process automation and continuous verification. Operating Models of Pharma 4.0 detailed Shown in Fig. 4. [18-25]



"Fig. 4. Operating Models of Pharma 4.0"

VI. THE NECESSITY OF AI TOOLS

Pharmaceutical companies are increasingly considering the adoption of AI due to their pursuit of expedited market entry for novel discoveries. Indeed, the pharmaceutical sector has been an early adopter of computer technology, significantly enhancing productivity. However, a notable challenge arises from the disparity between wet and dry labs, as the pace of data generation varies greatly. Some pharmaceutical firms have initiated clinical trials for AI-designed molecules, prompting others to recognize the urgency of AI integration. As with computers, AI is progressively permeating across industries, promising transformative effects. This evolution will redefine roles, empowering researchers, and scientists to achieve more within shorter time frames. Presently, a vast majority of major pharmaceutical companies have made substantial investments in AI technology and possess the expertise to leverage its potential. Impact and uses of AI in manufacturing shown in Fig. 5.



"Fig. 5. Impact of AI in Manufacturing"

A. Cyber-Physical Systems:

Cyber-physical systems form the backbone of Industry 4.0. At its essence, it entails linking conventional equipment to computers, yet its scope extends far beyond mere hardware adjustments. Since its inception in 2011, the concept of Industry 4.0 has undergone various interpretations and subdivisions concerning cyber-physical systems, leading to diverse perspectives and terminologies.

B. Artificial Intelligence:

The discussion on "learning" and "high-level cognitive decision-making" primarily resides at the algorithmic level, often managed by software, constituting artificial intelligence. Empowering machines to resolve problems by autonomously expanding their behaviors propels us toward a realm of self-regulating systems. Optimised production, improved energy management, and reduced downtime in smart factories are the immediate advantages of implementing suitable artificial intelligence. Presently, the adoption rate of artificial intelligence remains relatively low, ranging from 4% for small firms to 9% for those with 10 to 250 employees, but this is subject to rapid and significant change.

C. Internet of Things (IoT):

Devices with sensors, software, and other technologies built in for data exchange with other devices are included in the Internet of Things. These devices use artificial intelligence (AI) algorithms to analyse data and detect possible problems in advance by monitoring and controlling multiple manufacturing process aspects in real-time.

D. Big Data Analytics:

With the proliferation of automation and digitalization, Pharma 4.0 generates vast amounts of data during its processes, necessitating expanded data storage capacities. Big data analytics processes and analyzes these substantial datasets to extract actionable insights for optimizing manufacturing processes.

E. Robotics and Automation:

Automation and robotics simplify manufacturing procedures by lowering the need for human involvement, which lowers errors and boosts productivity.

F. Cloud Storage:

Cloud storage facilitates the storage and management of diverse data types, including manufacturing data, patient data, genomic data, supply chain data, and clinical trial data. Authorized personnel can access and analyze this data in real-time from any internet-connected device, ensuring data security through encryption and access controls

G. Blockchain:

Blockchain technology is essential to Pharma 4.0 because it improves medication safety, fights fraud and counterfeiting, increases supply chain efficiency, and assures regulatory compliance.

H. Remote Communication Technologies:

Pharma 4.0 relies heavily on teleconferencing, videoconferencing, and virtual collaboration tools to facilitate real-time communication between researchers, physicians, patients, and regulators at any point in the pharmaceutical value chain, regardless of geographic location. Fig. 6 shows the augmented and virtual reality.

I. Augmented and Virtual Reality:



"Fig. 6. Augmented and virtual reality"

AR and VR technologies play essential roles in Industry 4.0, aiding manufacturing companies in addressing challenges posed by volatile demand and evolving customer and supplier requirements. In the pharmaceutical sector, VR applications reduce design and production costs, maintain product quality, and expedite the transition from product concept to production. [25-40]

VII. AI INTEGRATION IN QUALITY MANAGEMENT SYSTEM

As technology continues to advance, the pharmaceutical industry remains vigilant in exploring innovative avenues to enhance quality management practices. While electronic quality management systems (eQMS) have already streamlined various aspects of quality management, the integration of artificial intelligence (AI) stands poised to catalyze further advancements in quality management protocols.

A. Enhancing Data Management through AI:

A pivotal advantage of incorporating AI into eQMS lies in its capacity to analyze extensive datasets swiftly and accurately. AI systems possess the capability to discern intricate data patterns and trends that might elude manual detection, thereby fostering informed decision-making, expeditious issue resolution, and ultimately bolstered quality control.
For instance, AI can be leveraged to scrutinize quality control test results, pre-emptively identifying potential issues before they escalate. Additionally, AI holds promise in uncovering patterns within customer complaints, affording businesses insights into underlying issues and facilitating the development of targeted solutions.

AI-driven Compliance Improvement:
Given the pharmaceutical sector's stringent regulatory landscape, regulatory compliance is paramount in quality management endeavors. By automating compliance procedures and furnishing real-time alerts for emerging issues, the incorporation of AI into eQMS can aid companies in upholding regulatory standards. Furthermore, AI's adeptness in identifying trends in quality issues enables proactive measures to address potential concerns pre-emptively. [42-49]

VIII. AI IN QUALITY BY DESIGN (QBD)

The central aim of this examination revolves around the integration of AI within the framework of Analytical Quality by Design (AQbD). Rooted in systematic and comprehensive methodologies, AQbD principles seamlessly align with the dynamic capabilities of AI.
The traditional standards are proving inadequate, prompting the integration of AI to serve as a catalyst for elevating quality assurance to unprecedented levels. The fusion of AQbD principles with AI technologies signifies more than just an incremental evolution; it represents a profound redefinition of pharmaceutical quality management at its core. Analytical Quality by Design (AQbD) and AI in Method Development:
In the ever-evolving landscape of pharmaceuticals, ensuring the quality and reliability of analytical methods stands as a paramount concern. Guided by Analytical Quality by Design (AQbD) principles, the development of these methods aims not only for effectiveness but also for robustness. Let us now explore how the integration of Artificial Intelligence (AI) in method development is revolutionizing this process, showcasing real-world instances of its transformative potential. Design of AQBD shown in Fig. 7.



"Fig. 7. Design of AQBD"

A. Accelerated Drug Formulation with AI-Optimized Methods:

Imagine a scenario where a pharmaceutical entity embarks on developing a new drug formulation. Traditionally, method development could span months, involving numerous experiments and manual adjustments to attain the optimal analytical method. However, with AQbD principles and AI integration, this timeline undergoes a significant compression. AI algorithms delve into vast datasets from initial experiments, discerning patterns and correlations between various method parameters and desired quality outcomes.
In real-time, the AI system proposes adjustments to these parameters, expediting the optimization process. This iterative learning approach facilitates swift identification of critical method parameters, ultimately resulting in the creation of a robust analytical method tailored to the specific drug formulation. The outcome is a streamlined and efficient development process, underscoring the potency of AI in method optimization within the AQbD framework.

B. Real-Time Quality Monitoring in Continuous Manufacturing:

In the realm of continuous manufacturing, where pharmaceuticals undergo uninterrupted production, real-time quality control assumes critical importance. AQbD principles steer the development of analytical methods adaptable to the continuous production milieu. The introduction of AI into this equation yields particularly significant benefits.
Envision a production line where medicines are continually manufactured. AQbD principles ensure that analytical methods

for quality control are designed with flexibility and adaptability in mind. AI, in this setting, monitors ongoing production processes in real-time. It scrutinizes data from various checkpoints, continuously learning and adjusting analytical method parameters to uphold desired quality standards.

For instance, if a critical parameter deviates from the norm, the AI system autonomously modifies the analytical method, safeguarding the pharmaceutical product's quality. This real-time adaptability, guided by AQbD principles and facilitated by AI, embodies a proactive stance towards quality control amidst the ever-changing landscape of continuous manufacturing. [50-54]

IX. CHALLENGES IN THE ADOPTION OF AI IN PHARMA

Although AI holds immense potential to redefine the pharmaceutical industry, its adoption presents numerous hurdles.

A. Unfamiliarity with the Technology:

For many pharmaceutical companies, AI remains shrouded in mystery, resembling a "black box" due to its novelty and complex nature.

B. Inadequate IT Infrastructure:

The existing IT applications and infrastructure lack compatibility with artificial intelligence, necessitating costly upgrades for pharma firms to integrate AI effectively.

C. Data Format Complexity:

A significant portion of pharmaceutical data exists in free text format, requiring extensive efforts to compile and format it for analysis, adding to the adoption challenges.

D. Regulatory Compliance:

Pharma 4.0 technologies demand advanced systems and software, necessitating adherence to stringent regulatory standards, posing a significant compliance challenge for pharmaceutical companies.

E. Data Privacy and Security:

As the pharmaceutical industry generates vast amounts of sensitive data through data analytics and AI, ensuring its privacy and security becomes paramount, especially in light of regulatory scrutiny.

F. Integration of Legacy Systems:

Many pharmaceutical companies rely on outdated systems that fail to interface with modern digital technology, requiring thorough planning and execution to overcome this obstacle.

G. Talent Acquisition and Retention:

Pharma 4.0 demands a new set of competencies, such as expertise in data analytics, artificial intelligence, and machine learning. Obtaining and maintaining top individuals with these competencies is a major challenge for pharmaceutical businesses.

H. Financial Constraints:

For smaller pharmaceutical companies or those with fewer resources, implementing Pharma 4.0 technology requires major expenditures in infrastructure, software, and manpower.

I. Intellectual Property Protection:

As digital technologies become more prevalent in pharma, concerns regarding intellectual property protection grow. Safeguarding intellectual property, including AI algorithms and hardware components, requires ongoing attention and legal measures to ensure adequate protection. [54-58]

X. CONCLUSION

In conclusion, the integration of AI into the pharmaceutical industry represents a transformative shift with profound implications. Despite facing various challenges in adoption, AI has demonstrated its potential to revolutionize numerous facets of pharmaceutical operations.

From drug discovery and development to manufacturing and quality control, AI has proven instrumental in accelerating processes, enhancing efficiency, and improving outcomes. Its ability to analyze vast datasets, identify patterns, and make predictions has streamlined decision-making and enabled the creation of personalized medicines. Moreover, AI has facilitated advancements in regulatory compliance, data privacy, and intellectual property protection, albeit with ongoing challenges that require careful attention and resolution. As the pharmaceutical landscape continues to evolve, AI will undoubtedly play an increasingly pivotal role, driving innovation, improving patient care, and ultimately reshaping the future of healthcare. [59-60]

REFERENCES

[1] Stankiewicz, R., & Łobejko, S. (2018). Industry 4.0 concept–literature review and future directions. International Journal of Management and Enterprise Development, 17(1), 36-52.

[2] Lee, J., Bagheri, B., & Kao, H. A. (2015). A cyber-physical systems architecture for industry 4.0-based manufacturing systems. Manufacturing Letters, 3, 18-23.

[3] N.Sarah Arden, Adam C. FIsher , Industry 4.0 for the pharmaceutical manufacturing : Preparing for the smart factories of the future. International journal of pharmaceutics 602 (2021) 120554

[4] Michael rubmann , inudustry 4.0 : The future of productivity and growth in manufacturing industries , april 09 , 2015

[5] Neugebauer R, Hippmann S, Leis M, Landherr M (2016) Industry 4.0: form the perspective of applied research. In: 49th CIRP conference on manufacturing systems, pp 2–6

[6] Zhong RY, Xu X, Klotz E, Newman ST (2017) Intelligent manufacturing in the context of Industry 4.0: a review. Engineering 3:616–630

[7] Gilchrist A (2016) Industry 4.0. Apress, Berkeley

[8] Lu, Y., Morris, J., & Freiheit, T. (2019). How to implement industry 4.0 in small and medium-sized enterprises: An empirical study. Production Planning & Control, 30(5-6), 439-452.

[9] Xu LD, Xu EL, Li L (2018) Industry 4.0: state of the art and future trends. Int J Prod Res 56(8):2941–2962

[10] Varghese A, Tandur D (2015) Wireless requirements and challenges in Industry 4.0. In: Proceedings of 2014 international

conference on contemporary computing and informatics, IC3I 2014, pp 634–638

[11] Devansh Sharma. Prachi Patel , A comprehensive study on industry 4.0 in the pharmaceutical industry for sustainable development , Environmental Science and Pollution Research (2023) 30:90088-90098

[12] Schwab, K. (2017). The Fourth Industrial Revolution. Currency.

[13] Vaidya S, Ambad P, Bhosle S (2018) Industry 4.0—a glimpse. Procedia Manuf 20:233–238

[14] Kagermann, H., Wahlster, W., & Helbig, J. (2013). Recommendations for implementing the strategic initiative INDUSTRIE 4.0. Forschungsunion.

[15] Jabłońska, A., Nawrocka, A., Rutkowska, A., & Szulc, J. (2020). Pharma 4.0 as an element of Industry 4.0 in pharmaceutical industry. Management and Production Engineering Review, 11(4), 40-49.

[16] Rautert, T., & Leker, J. (2018). Pharma 4.0–Innovative Business Models and Industry Transformation. In Managing Digital Transformation (pp. 207-222). Springer, Cham.

[17] Dej, T., Prorok, K., & Stryjski, R. (2018). The Concept of Industry 4.0 in Pharmaceutical Companies. Journal of International Studies, 11(2), 86-98.

[18] N.Nuraela Arief , Pharma 4.0 : Analysis on core competence and digital levelling implentation in pharmaceutical industry in indonesia, Heliyon 8 (2022) e10347

[19] Bayram B, Ince G (2018) Advances in robotics in the era of industry 4.0. In: Industry 4.0: managing the digital transformation. Springer series in advanced manufacturing

[20] Rossmann, A., & Torunski, T. (2018). Towards Pharma 4.0. The transformational paradigm shift in the pharmaceutical industry. Current Issues in Pharmacy and Medical Sciences, 31(2), 87-92.

[21] Henneberg, S. C., & Zocchi, A. (2020). The role of platforms in Pharma 4.0: enabling connected health in an interconnected ecosystem. Drug Discovery Today, 25(7), 1174-1181.

[22] Sliva, A., & Zwolinski, P. (2018). Pharma 4.0–concept and research directions. Polish Journal of Management Studies, 17, 274-284.

[23] Ekins, S., 2016. The Next Era: Deep Learning in Pharmaceutical Research. Pharm. Res. 33 (11), 2594–2603.

[24] Meyer, P. (2017). Industry 4.0: Opportunities and Challenges of the Industrial Internet. Retrieved from https://www.bcg.com/industries/industrials/industry-4-0-opportunities-and-challenges-of-the-industrial-internet

[25] Rubmann, M., Lorenz, M., Gerbert, P., Waldne R, M., Justus, J., Engel, P., & Harnisch, M. (2015). Industry 4.0: The Future of productivity and growth in Manufacturing industries. Boston Consulting Group, 9(1), 54–89. [Google Scholar]

[26] Li, Y., Huang, C., Ding, L., Li, Z., Pan, Y., Gao, X., & Zheng, M. (2021). Artificial intelligence in pharmaceutical industry: A comprehensive review and a glimpse into the future. Bioinformatics, 37(20), 3689–3711.

[27] Li, Y., Huang, C., Ding, L., Li, Z., Pan, Y., Gao, X., & Zheng, M. (2021). Artificial intelligence in pharmaceutical industry: A comprehensive review and a glimpse into the future. Bioinformatics, 37(20), 3689–3711.

[28] Agapito, G., Hockenberry, A. J., & Velez, D. O. (2020). Application of artificial intelligence in pharmaceutical product formulation and process development. International Journal of Pharmaceutics, 587, 119648.

[29] Gupta, A., & Banerjee, P. (2019). Advances in artificial intelligence: Current landscape and future directions in the pharmaceutical industry. Applied Artificial Intelligence, 33(9), 792–807.

[30] McLean, D. (2019). The ethics of artificial intelligence in health care. British Medical Bulletin, 129(1), 5-14.

[31] Ullah, M. W., Kim, D. W., & Park, J. K. (2021). Artificial intelligence and machine learning in pharmaceutical product formulation. Pharmaceutics, 13(10), 1673.

[32] Ch. Krishnaswamy, Swarupa Arvapalli, Artificial Intelligence in Pharma Industry – A Review, October 2019.

[33] Avery Philips, How Artificial Intelligence Is Changin Modern Life 2018.www.becominghuman.ai.

[34] Osama Khan, Mohd Parvez, The Future of Pharmacy : How AI is revolutionizing the industry, April 2023.

[35] US Food and Drug Administration. (2011). Guidance for industry, Q8 (R2) pharmaceutical development. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER).

[36] Mak, K.-K. and M.R.Pichika, Artificial Intelligence in drug development:

[37] Muñoz-Saavedra, L. L.-A.-M. (2020). Augmented and virtual reality evolution and future tendency. Applied sciences, 10(1), 322.present status And future prospects, Drug discovery today, 2019. 24(3): p. 773-780.

[38] Arinez, J., Chang, Q., Gao, R., Xu, C., Zhang, J., 2020. Artificial Intelligence in Advanced Manufacturing: Current Status and Future Outlook. J. Manuf. Sci. Eng. 142 (11), 16.

[39] Debnath, S., & Bauman, T. M. (2020). Artificial intelligence: shaping the future of pharmaceutical sciences. Future Medicinal Chemistry, 12(10), 877–880.

[40] Shah, R. R. (2020). Impact of artificial intelligence on drug discovery, development and regulation: A review. Clinical Pharmacology & Therapeutics, 107(3), 547–556.

[41] Koutsoukas, A., Monaghan, K. J., & Li, X. (2021). Machine learning and AI-based approaches for bioactive ligand discovery and activity prediction in drug discovery. Bioorganic & Medicinal Chemistry Letters, 51, 127905.

[42] Tao, F., Cheng, Y., Xu, L. D., Zhang, L., & Li, B. H. (2018). CCIoT-CMfg: cloud computing and internet of things-based cloud manufacturing service system. IEEE Transactions on Industrial Informatics, 14(1), 283-294.

[43] Bottani, E. a. (2019). Augmented reality technology in the manufacturing industry: A review of the last decade. IISE Transactions, 51(3), 284-310.

[44] Zeng, S., Xu, X., & Yin, J. (2017). From cloud computing to cloud manufacturing: A comprehensive review and future directions. Robotics and Computer-Integrated Manufacturing, 43, 98-110.

[45] Jiang, L., & Cui, L. (2020). Application of artificial intelligence in quality management of product manufacturing. In Proceedings of the International Conference on Industrial Engineering and Operations Management (IEOM) (pp. 1-6).

[46] Pohl, E. A., & Vogt, D. M. (2019). Artificial intelligence in quality management. In Advances in Manufacturing Technology XXXIII (pp. 365-370). Springer, Cham.

[47] Nagy, G. N., & Szabó, R. Z. (2018). The role of artificial intelligence in quality management systems. In 2018 IEEE 16th International Symposium on Intelligent Systems and Informatics (SISY) (pp. 000217-000222). IEEE.

[48] Muruganantham, A., Rana, N. P., Dwivedi, Y. K., & Kapoor, K. K. (2019). Leveraging artificial intelligence to advance quality management in manufacturing. Robotics and Computer-Integrated Manufacturing, 57, 23-34.

[49] https://www.globaltechcouncil.org/artificial-Intelligence/artificial-intelligence-in-the- Pharmaceutical-industry/

[50] https://resource.ddregpharma.com/insights/artifIcial-intelligence-impact-on-the-global Pharma-industry/

[51] Skratch, A., & Choudhury, A. (2021). Quality by Design in Pharmaceutical Industry: A Review. Journal of Pharmaceutical Innovation, 1-10.

[52] Lawal, M., & Khamis, M. M. (2017). Advanced quality by design: A Literature Review. Advanced Pharmaceutical Bulletin, 7(1), 15-24.

[53] Wang, X., Vashisth, S., & Lu, J. (2020). Artificial Intelligence (AI)-Driven Quality by Design (QbD): A Review. Pharmaceutical Research, 37(9), 173.

[54] Ghassemi, M., & Alaa, A. M. (2019). Artificial intelligence in health care: challenges and opportunities. Stanford University: Institute for Computational and Mathematical Engineering Technical Report, 2019-01.

[55] Lopes, J. A., & Ferreira, E. C. (2021). Artificial Intelligence and Quality by Design in Drug Formulation and Process Development. Pharmaceutics, 13(8), 1258.

[56] Gupta, A., Dhiman, G., & Agarwal, S. M. (2019). AI in healthcare: Challenges and directions for global implementation. Artificial Intelligence in Healthcare, 3, 100013.

[57] https://www.expresspharma.in/advertise-with-Us/ artificial intelligence pharma industries

[58] https://usmsystems.com/artificial-intelligence-In-pharma/

[59] Saponara, S. (2021). The role of AI in digital healthcare: opportunities and challenges. Computer Communications, 176, 1-11.

[60] Zhang, L., Tan, Y., Zhang, C., & Chen, R. (2021). Challenges and Opportunities of Artificial Intelligence in the Pharmaceutical Industry. Advanced Theory and Simulations, 4(1), 2000243.

.